A Phase 2 study of nivolumab in combination with modified FOLFIRINOX for metastatic pancreatic cancer
{{output}}
Background: Nivolumab with modified FOLFIRINOX (mFOLFIRINOX) may have additive antitumour effects while minimising chemotherapy cytotoxicity. We assessed the efficacy and safety of nivolumab+mFOLFIRINOX in metastatic pancreatic c... ...
